IDA Solutions Clarisse Morris, MA January 2006

Slides:

Advertisements

Similar presentations

The TB Alliance-Bayer Moxifloxacin Deal

Advertisements

Providing Quality Medicines for People Living with and Affected by HIV and AIDS Supply Chain Management System Project The Partnership for Supply Chain.

Strategic Information for Anti-RetroViral Treatment Programmes Workshop WHO and UNAIDS Geneva June 30- July Ties Boerma HIV Department Surveillance,

PROCURING AND DISTRIBUTING ARVs AND OTHER A.R.T COMMODITIES IN MALAWI Technical Briefing for Consultants in Procurement and Supply Management for HIV,

Key1 World Bank Training Program on HIV/AIDS Drugs Training Module 3 Selection and Quantification based on the World Bank document Battling HIV/AIDS: A.

Group III: Demand Forecasting

Technical Briefing Seminar for PSM Consultants for HIV/AIDS, TB and Malaria PRIVATE SECTOR ART PROVIDER NETWORK IN KENYA INITIATIVE OF FHI/KMA Presented.

National PSM Coordination Mechanism Dr Vincent Habiyambere WHO/HIV Department AIDS Medicines & Diagnostics Service (AMDS) Bangkok, July 2005.

World Health Organization

Review of HIV and Opportunistic Infections (OI) in Children

"3 by 5" progress December 2005 Progress on global access to HIV antiretroviral therapy | 12 April |2 | Antiretroviral therapy coverage in low-

Implementation of Diagnostics in Resource-Limited Settings Amy Piatek Global Health Bureau, Office of Health, Infectious Diseases & Nutrition U.S. Agency.

HIV 101 Review Evaluation Center for HIV and Oral Health Boston University School of Public Health Health & Disability Working Group.

Global Fund – PEPFAR Coordination The Tanzania Example Dr. Fatma Mrisho Chairperson TACAIDS.

Iman Wanis, Cushla Coffey, Shaffiq Essajee, and Philippa Easterbrook World Health Organization, HIV Department (ATC) Geneva, Switzerland July 2011 COSTING.

8 th European Forum – Gastein 2005 To cure - occasionally To relieve – often To comfort – always (Hippocrates, 400 AC) PALLIATIVE CARE FOR PLWA IN MOLDOVA.

HIV/AIDS Isabelle Récaborde Dr. Frigon Chemistry SL – Block F Option - Medicine and Drugs.

Prevention and improved treatment of communicable diseases (HIV/AIDS and TB), including increasing preparedness for bioterrorism and epidemics Anneli Taal,

Improving Access for Quality-Assured TB Medicines and Diagnostics Dr Kaspars Lunte Team Leader Sourcing and Special Projects, GDF Copenhagen, IPC Meeting.

Affordable healthcare Product Selection for Opportunistic Infections IDA HIV/AIDS Group, Nienke Gruppelaar “ HIV does not kill, opportunistic infections.

Systems Approach1. 2 A Systems Approach to the Design of Comprehensive HIV/AIDS programs Malcolm Bryant, MB.BS., MPH.

Botswana Experience on Public- Private Partnerships Joconiah Chirenda, MD, MPH, MBA Global Business Coalition on.

1 Starting ART in the Context of Opportunistic Infections HAIVN Harvard Medical School AIDS Initiative in Vietnam.

PROGRAM UPDATE OVERCOMING HIV/AIDS EPIDEMICS IN UKRAINE NATIONAL PROGRAM SUPPORTED BY GFATM COMPONENT: TREATMENT, CARE AND SUPPORT Presentation by Treatment,

Downloaded from Current Status of ART Opportunities & Challenges Kibrebeal Melaku,MD Associate Professor.

WHO-HIV Department Strategic Information Unit AIDS Medicines and Diagnostics Service Contribution to Access to medicines Technical Briefing Seminar, November.

Review experiences of global ARV shortages Clarisse Morris, MA February 2006.

TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.

From 3by5 to Universal Access to HIV/AIDS Treatment: AMDS Technical Briefing Seminar for Consultants on Procurement and Supply Management for HIV, TB and.

AIDS. Most important facts Acquired immune deficiency syndrome Caused by the human immunodeficiency virus(HIV). Firstly recognized on June 5, Impossible.

Affordability of HIV/AIDS treatment in developing countries: an analysis of ARV drug price determinants Luis Sagaon Teyssier; Yves Arrighi; Boniface Dongmo.

World Health Organization "3 by 5" Target Treat 3 million by 2005.

The National HIV Counselling and Testing Campaign and Treatment Expansion in South Africa: A return on investments in combination prevention XIX International.

Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.

Achievements and impacts of WHO prequalification to date MSF perspective Carine Werder MSF international pharmacist coordinator Geneva, 11 th February.

De Beers Response to HIV/AIDS 19 th June 2006 World Bank Group- CommDev Workshop.

HIV/AIDS By Paul G.. Introduction: What is HIV/AIDS? ◦ HIV stands for Human Immunodeficiency Virus. ◦ AIDS stands for Acquired Immunodeficiency Syndrome.

The price trends of HIV/AIDS medicines: Finding and using data Dr. Perriëns Joseph Coordinator SSH Unit, WHO.

Number of people receiving antiretroviral therapy in

TB- HIV Collaborative activities in Romania- may 2006 status

Zimbabwe’s shift towards treat all: national country context

Chapter 85 HIV and AIDS.

What’s Your Health IQ? True or False

Expanding ARV treatment in developing countries: Issues and Prospects

HIV Opportunistic infections

Access framework HIV/AIDS, TB and Malaria

Keeping Kids in the Picture: Pediatric TB in the COPs process

Access to Essential Medicines and Supplies

From Balance sheet to economic analysis

دانشگاه علوم پزشکی بوشهر برنامه ملی مبارزه با بیماریهای واگیر

"3 by 5" progress December 2005.

B. Dongmo Nguimfack AMDS TCO Unit/HIV, WHO

Antiretroviral therapy coverage in sub-Saharan Africa,

Medicine in third world countries

AMDS Products, events and issues.

Projected new adult infections and total adult deaths in sub-Saharan Africa, in millions, by the year 2020: Impact of three scenarios compared to baseline.

Access to HIV/AIDS Medicines The 3x5 strategy

A Technical Guide to the Contemporary Context of HIV/AIDS Procurement of Medicines and Supplies under Bank funding Strengthening Fiduciary Management in.

Commonalities across treatments and diseases: A brief overview

Principles of Financial Management and Disbursement

Anthony D Harries Ministry of Health, Malawi

Global Drug Facility: Providing Access to Medicines and Commodities for Tuberculosis Thomas Moore Manager GDF Geneva, 19 November 2009.

WHO Global HIV/AIDS Staff Meeting

Drug Resistance and the Three Great Pandemics

Presentation for Second Meeting of the Global TB/HIV Working Group

The Global Fund to Fight AIDS, Tuberculosis and Malaria

Geneva, Switzerland June 2002

Investigate the Treatment of Infectious Diseases

DSD and TB/HIV services in Zimbabwe

Intellectual Property Rights in Medicines Procurement

Presentation transcript:

IDA Solutions Clarisse Morris, MA January 2006 25 June 2018 Current issues in selection & procurement planning of drugs to treat and prevent opportunistic infections Clarisse Morris, MA January 2006

HIV treatment is not just about ARVs! IDA Solutions 25 June 2018 HIV treatment is not just about ARVs! Source: A Technical Guide to the Contemporary Context of HIV/AIDS: Procurement of Medicines and Supplies under Bank funding. Strengthening Fiduciary Management in Multi-Sectoral National HIV/AIDS Program for Sub-Saharan Africa. Presentation for the Network of National HIV/AIDS Program Practitioners in Africa (NAPPA) and World Bank. July 2003.

Most common OIs Bacterial diseases Protozoal diseases Fungal diseases IDA Solutions 25 June 2018 Most common OIs Bacterial diseases Protozoal diseases Fungal diseases Viral diseases HIV associated malignancies

Why are OIs complex? Large number of opportunistic infections IDA Solutions 25 June 2018 Why are OIs complex? Large number of opportunistic infections Many OIs have the same symptoms Some OIs may mask others Large amount of medicines OI treatment is not standard Interaction between ARVs and OI drugs FDCs and single compound drugs

Drug pricing and availability issues IDA Solutions 25 June 2018 Drug pricing and availability issues Cytomegalovirus (CMV) retinitis: Only expensive branded drug available. MDR-TB: Much more expensive. Few manufacturers for some drugs.

Drug pricing and availability issues (cont’d) IDA Solutions 25 June 2018 Drug pricing and availability issues (cont’d) Price reductions to increase availability MDR-TB: capreomycin and cycloserine Fungal diseases: fluconazole

References http://www.thewellproject.org/Diseases_and_Conditions/Opportunistic_Infections/OI_Chart.pdf Sources and prices of selected drugs and diagnostics for PLWAs by UNICEF,UNAIDS, WHO, MSF, May 2002 http://www.accessmed-msf.org/prod/publications.asp?scntid= 26620021230454 &contenttype=PARA& Selection of TB medicines and supplies, MSH, 2004 http://www.who.int/3by5/capacity/4)ProductSelectionTBBKK.ppt Fluconazole donation programme, E-drug, December 2004 http://www.essentialdrugs.org/edrug/archive/200412/msg00030.php www.diflucanpartnership.org